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Summary
Inhibition of angiogenesis is an important new modality for cancer treatment. 2-methoxyestradiol (2ME2) is a novel antitumor
and antiangiogenic agent, currently in clinical trials, whose molecular mechanism of action remains unclear. Herein, we
report that 2ME2 inhibits tumor growth and angiogenesis at concentrations that efficiently disrupt tumor microtubules
(MTs) in vivo. Mechanistically, we found that 2ME2 downregulates hypoxia-inducible factor-1 (HIF) at the posttranscriptional
level and inhibits HIF-1-induced transcriptional activation of VEGF expression. Inhibition of HIF-1 occurs downstream of
the 2ME2/tubulin interaction, as disruption of interphase MTs is required for HIF- downregulation. These data establish
2ME2 as a small molecule inhibitor of HIF-1 and provide a mechanistic link between the disruption of the MT cytoskeleton
and inhibition of angiogenesis.
Introduction 2001; Masson et al., 2001) by specific HIF-prolyl hydroxylases
in the presence of iron and oxygen (Bruick and McKnight, 2001;
Epstein et al., 2001). The hydroxylated protein is then recognizedAngiogenesis, the development of new blood vessels from pre-
existing vasculature, is essential during embryonic develop- by the von Hippel-Lindau tumor suppressor protein (pVHL),
which functions as an E3 ubiquitin ligase. The interaction be-ment. In the adult, angiogenesis occurs under physiological
conditions in highly regulated processes such as wound healing tween HIF-1 and pVHL is further accelerated by acetylation
of lysine residue 532 through an N-acetyltransferase (Jeong etand ovulation. Under pathological conditions, angiogenesis
supports the development of many diseases, including cancer, al., 2002). Under hypoxia, HIF-1 is not hydroxylated, which
prevents its interaction with pVHL and its subsequent ubiquitina-rheumatoid arthritis, psoriasis, macular degeneration, and dia-
betic retinopathy (Folkman, 2001). In the case of cancer, angio- tion and degradation. Following hypoxic stabilization, HIF-1 is
translocated to the nucleus where it heterodimerizes with HIF-1genesis is essential for the growth, progression, and metastasis
of a tumor and, thus, agents that inhibit angiogenesis are attrac- (ARNT, arylhydrocarbon receptor nuclear translocator) and acti-
vates the transcription of more than 40 genes important fortive therapeutic options (Hlatky et al., 2002; Weidner et al.,
1991). Vascular endothelial growth factor (VEGF) is a major adaptation and survival under hypoxia (Brahimi-Horn et al.,
2001; Harris, 2002; Maxwell and Ratcliffe, 2002; Semenza,mediator of angiogenesis (Carmeliet et al., 1996; Risau, 1997);
whose expression is induced under hypoxic conditions (Gold- 2002).
HIF-1 is overexpressed in more than 70% of human can-berg and Schneider, 1994; Minchenko et al., 1994; Shweiki et
al., 1992). Induction of VEGF under hypoxic conditions is a cers and their metastases compared to their adjacent normal
tissue, including breast, prostate, brain, lung, and head andmultistage process in which the  subunit of hypoxia-inducible
factor-1 (HIF-1) plays a key role (Forsythe et al., 1996). HIF- neck cancers (Aebersold et al., 2001; Beasley et al., 2002; Birner
et al., 2000, 2001; Blancher et al., 2000; Bos et al., 2001; Giatro-1 is rapidly degraded by the proteasome under normoxic con-
ditions. This occurs through HIF-1 protein hydroxylation on manolaki et al., 2001; Koukourakis et al., 2002; Schindl et al.,
2002; Talks et al., 2000; Zhong et al., 1999). However, the pre-proline residues 402 and 564 (Ivan et al., 2001; Jaakkola et al.,
S I G N I F I C A N C E
2ME2 is a well-tolerated orally active small molecule with antiangiogenic and antitumor activity currently in phase I/II clinical trials
whose exact mechanism of action is not known. Herein, we report on a novel mechanism mediating the antitumor and antiangiogenic
activity of 2ME2. Utilizing a pharmacological approach and xenograft models, we showed that at concentrations that are efficacious
in vivo, 2ME2 depolymerizes microtubules and blocks HIF-1 nuclear accumulation and HIF-transcriptional activity. This mechanism
is shared by other microtubule-targeting drugs used in the clinic. Our data provide evidence for a link between microtubule
cytoskeleton disruption, HIF dysregulation, and inhibition of angiogenesis.
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cise role of HIF in tumor development remains highly controver- 1B). Treatment with 2ME2 was specific for the regulated  sub-
unit of HIF-1 and HIF-2, but had no effect on the protein levelssial due to the conflicting results of several tumor models. While
one study found that genetic disruption of the HIF-1 locus of HIF-1 or other transcription factors such as c-fos, NF-B
(Figure 1A, lower panel), and c-jun (data not shown).results in the accelerated growth of poorly vascularized
HIF-1/ teratocarcinomas (Carmeliet et al., 1998), other stud- To investigate the effects of 2ME2 treatment on HIF-1 tran-
scriptional activity, we measured VEGF protein levels in theies have shown that the absence of HIF activity in different
models impairs tumor growth (Hopfl et al., 2002; Maxwell et al., conditioned media from 2ME2-treated MDA-MB-231 cells. Con-
sistent with the reduced levels in HIF-1 protein by 2ME2, VEGF1997; Ryan et al., 1998, 2000). Additional evidence in support
of the notion that HIF is not necessarily a positive regulator of levels were also significantly decreased in a dose-dependent
manner under both normoxic and hypoxic conditions (Figuretumor growth emerged from a recent study where ES cells
lacking VHL and constitutively expressing HIF- subunits did 1C). Similar results were obtained following treatment of PC-3
cells with 2ME2 (data not shown).not promote tumor growth (Mack et al., 2003).
2-Methoxyestradiol (2ME2) is a naturally occurring derivative To examine whether the downregulation of VEGF expression
after exposure of cells to 2ME2 was the result of a direct effect onof estradiol and has been shown to be an orally active, well-
tolerated small molecule that possess antitumor and antiangio- HIF-1, we tested HIF-1 transcriptional activity using a reporter
gene assay (Figure 1D). PC-3 cells were transiently transfectedgenic activity (Pribluda et al., 2000). 2ME2 has low affinity for
estrogen receptors  and , and its antiproliferative activity is with a construct containing Luciferase gene under the control of
the hypoxia response elements (HRE) from the VEGF promoterindependent of the interaction with those receptors (LaVallee
et al., 2002). Several mechanisms have been proposed for 2ME2 (Post and Van Meir, 2001). The results show that 2ME2 treatment
also blocked the hypoxia-induced transcriptional activity ofactivity, including those mediated by its ability to bind to the
colchicine binding site of tubulin (Cushman et al., 1995; D’Amato HIF-1. To further investigate the effects of 2ME2 treatment on
the DNA binding activity of HIF, we performed an electrophoreticet al., 1994) and the inhibition of superoxide dismutase enzy-
matic activity (Huang et al., 2001). However, some of these mobility shift assay (see Supplemental Figure S1 at http://www.
cancercell.org/cgi/content/full/3/4/363/DC1). Consistent withfindings have been disputed (Attalla et al., 1996; Kachadourian
et al., 2001), and the process by which 2ME2 inhibits tumor the gene reporter assay (Figure 1D), HIF DNA binding activity
was also attenuated in the 2ME2-treated samples. Collectively,growth and angiogenesis is still not well understood.
Here we report on a novel mechanism mediating the antitu- these results suggest that 2ME2 inhibits the hypoxia-induced
DNA binding and transcriptional activity of HIF.mor and antiangiogenic activity of 2ME2. Our findings demon-
strate that 2ME2 destabilizes microtubules at doses that are To determine whether downregulation of HIF-1 by 2ME2
occurred at the transcriptional level, we treated MDA-MB-231efficacious in vivo. At concentrations that have antiproliferative
activity in tumor cells in vitro, 2ME2 blocks HIF-1 nuclear cells with 2ME2 and performed Northern blot analysis (Figure
2A). HIF-1 mRNA levels were not significantly changed byaccumulation and HIF-1 activity by an oxygen- and proteasome-
independent pathway. We further show that this mechanism is 2ME2 even at very high concentrations (100 M). Similar results
were obtained when we analyzed the expression levels ofshared by other MT-targeting drugs, such as taxol, and we
provide evidence for a link between the microtubule cytoskele- HIF-1 mRNA with quantitative RT-PCR (data not shown). As
expected, hypoxic exposure of the untreated cells resulted inton and HIF regulation.
a robust induction (20-fold) induction in VEGF mRNA (Figure
2A). 2ME2 treatment significantly decreased VEGF mRNA underResults
normoxia (16-fold decrease) and hypoxia (41-fold decrease). It
is of note that 2ME2 inhibited VEGF mRNA (Figure 2A) and2ME2 reduces expression of HIF-1 and VEGF
in prostate and breast cancer cells secretion (Figure 1C) under normoxic conditions as well. This
finding is consistent with the inhibition of HIF-1 protein levels2ME2 is an effective inhibitor of tumor growth and angiogenesis
in numerous in vivo models (Fotsis et al., 1994; Klauber et al., by 2ME2 under normoxia. This could be explained by the notion
that regulation of VEGF expression in cancer cells with substan-1997; Pribluda et al., 2000). Although various molecular targets
have been proposed for this compound, its mechanism of action tial normoxic levels of HIF-1 protein is mediated in part by
HIF. In addition, 2ME2 treatment inhibited two other HIF-1 targetremains unclear. HIF-1 is a proangiogenic transcription factor
stabilized and activated under hypoxia. HIF-1 activates angio- genes, namely Glut-1 glucose transporter and endothelin-1
(ET-1). This result further confirms that 2ME2 inhibits HIF-1-genesis via transcriptional activation of VEGF, among other
genes, and consequently is an important tumor survival factor. mediated transcriptional activation of target genes, including
VEGF, without affecting the transcription of HIF-1 itself.In this study, we sought to investigate whether regulation of the
HIF-1 pathway could contribute to the antiangiogenic effects To obtain a better understanding of the processes involved
in HIF-1 inhibition by 2ME2, we studied the effect of 2ME2of 2ME2. We first examined the effects of 2ME2 treatment on
HIF-1 protein in the human prostate cancer cells PC-3 (Figure on HIF-1 posttransciptional regulation. We examined 2ME2
effects on HIF-1 protein stability by using the protein transla-1A) and in the human breast cancer cells MDA-MB-231 (Figure
1B). As shown in Figure 1, 2ME2 treatment of PC-3 and MDA- tion inhibitor cycloheximide (CHX) (Figure 2B) and a pulse-chase
assay (Figure 2C). In the presence of CHX, new protein synthesisMB-231 cells reduced the levels of nuclear and total HIF-1
protein as detected in nuclear (NE) and whole-cell extract (WCE) is inhibited, thus HIF-1 levels would predominantly reflect the
degradation process of HIF-1 protein. Untreated or 2ME2-preparations. This inhibition was dose dependent and seen un-
der both normoxic and hypoxic conditions. HIF-2, which has treated cells were exposed to CHX for various times and HIF-
1 protein levels were analyzed by Western blotting. Within 10been reported to be regulated similarly to HIF-1 (Semenza,
2000; Wenger, 2000), is also downregulated by 2ME2 (Figure min of exposure to CHX (Figure 2B), HIF-1 protein levels from
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Figure 1. 2ME2 inhibits HIF-1 activity and expression of VEGF in PC-3 and MDA-MB-231 cells
A: PC-3 cells were treated with increasing concentrations of 2ME2 for 16 hr and then subjected to hypoxia, or they remained in normoxia for an additional
6 hr. Nuclear extracts (NE) or whole-cell extracts (WCE) were analyzed by SDS-PAGE and immunoblotted with an antibody against HIF-1. The blots were
stripped and reprobed with HIF-1, actin, c-Fos, or NF-B p65.
B: MDA-MB-231 cells were treated with 2ME2 as described in (A), and NE were resolved by SDS-PAGE, transferred, and immunoblotted with antibodies
against HIF-1, HIF-2, and Topoisomerase I (TOPO-I).
C: The conditioned media from MDA-MB-231 cells incubated with 2ME2 were analyzed for VEGF expressed as pg/ml per the total amount of protein in
each well.
D: PC-3 cells transiently transfected with pBI-GL V6L were treated with vehicle or 100 M 2ME2 under normoxic and hypoxic conditions. Relative luciferase
activity represents units per g of protein in each assay point. Columns, means; bars, SD; n  3; *, p  0.05.
both untreated and treated cells were decreased to about 60%. tion and degradation through the proteasome, we performed
the experiments shown in Figure 2E and Figure S2 (see Supple-Although the intensity of the HIF-1 signal is different at the
zero time point, the degradation rates of HIF-1 protein are mental Data on Cancer Cell website). PC-3 cells were treated
with 2ME2 in the presence or absence of the proteasome inhibi-similar in the absence or the presence of 2ME2 (Figure 2B).
This was further confirmed when cells were labeled with 35S- tor MG-132 (Figure 2E). In untreated cells, MG-132 resulted as
expected in enhanced HIF-1 protein levels and multiple highermethionine and pulse-chased in the presence or absence of
2ME2, and HIF-1 protein levels were then analyzed. The half- molecular weight species, which most likely correspond to poly-
ubiquinated HIF-1 protein conjugates (Figure 2E, arrows). Inlife of HIF-1 from 2ME2-treated cells was approximately 1.5
hr compared to 2.3 hr in the untreated cells. Again, as shown 2ME2-treated cells, however, MG-132 did not restore the inhibi-
tory effect of 2ME2 on HIF-1 protein levels in hypoxia or nor-in the graph by the slope of the two curves, the rates of HIF-
1 protein loss are similar under both conditions. Thus, 2ME2 moxia, suggesting that 2ME2 does not increase HIF-1 protea-
somal-mediated degradation. To further examine whether 2ME2does not seem to directly affect HIF-1 protein stability since
the rate of decrease of HIF-1 protein from both assays (Figures effects could be attributed to enhanced HIF-1 ubiquitinylation,
we transiently transfected cells with FLAG-tagged HIF-1 and2B and 2C) is similar in treated and untreated cells.
Following this observation, we next examined the effect of examined the accumulation of the ubiquitinated forms of HIF-1
in the presence or absence of 2ME2 (see Supplemental Figure2ME2 on HIF-1 protein translation. PC-3 cells were labeled
with 35S-methionine in the presence or absence of 2ME2 for the S2 on Cancer Cell website). In the presence of 2ME2, there was
no change in the amount of ubiquinated HIF-1 compared toindicated times (min) (Figure 2D). After 15 min of labeling, HIF-
1 protein synthesis was at least 10-fold higher in the untreated control, indicating that 2ME2 affected HIF-1 prior to the ubiqui-
nitation step.cells compared with the 2ME2-treated ones (Figure 2D). To-
gether with the results of the protein stability experiments, this Although, we cannot exclude an indirect effect of 2ME2 on
HIF-1 protein degradation through proteasome-independentresult suggests that 2ME2 treatment inhibits HIF-1 protein
synthesis rather than enhancing its degradation. To further ex- pathways, our results together with reports on other small mole-
cules (e.g., geldanamycin) known to accelerate HIF-1 proteinclude the possibility that 2ME2 accelerates HIF-1 ubiquitina-
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Figure 2. 2ME2 has no effect on HIF-1 mRNA levels or rate of protein degradation
A: Total RNA was prepared from 2ME2-treated MDA-MB-231 cells under normoxic and hypoxic conditions, and Northern blotting was performed with 32P-
labeled HIF-1 and VEGF165, Glut1, ET-1 probes. -actin is shown as a loading control. Quantification of the expression levels of VEGF by densitometry was
performed using -actin.
B: Upper panel: PC-3 cells were treated overnight with either vehicle (0.01% DMSO) or 10 M 2ME2 and cycloheximide (CHX) was added at a final
concentration of 10 g/ml for the indicated time. Equal amounts of protein from each sample were resolved by SDS-PAGE, and Western blotting was
performed with antibodies against HIF-1 or actin. Lower panel shows quantification of the HIF-1 signal by densitometry following normalization to actin
levels. HIF-1 levels from untreated cells or 2ME2-treated cells are arbitrarily given the value of 100%.
C: PC-3 cells were labeled with 35S-methionine and pulse-chased in complete medium containing either 0.1% DMSO or 100 M 2ME2 for the indicated
time (h). Upper panel: equal amounts of protein from each cell lysate were subjected to immunoprecipitation with anti-HIF-1 antibody, resolved by SDS-
PAGE, and subjected to autoradiography. Lower panel: quantification of the autoradiographic HIF-1 signal by densitometry.
D: PC-3 cells were pretreated overnight with either vehicle (0.025% DMSO) or 25 M 2ME2. The cells were then labeled with 35S-methionine in the presence
or absence of 25 M 2ME2 for the indicated time (min). Upper panel: equal amounts of protein from each cell lysate were subjected to immunoprecipitation
with anti-HIF-1 antibody, resolved by SDS-PAGE, and subjected to autoradiography. Lower panel: quantification of the autoradiographic HIF-1 signal by
densitometry.
E: PC-3 cells were treated with 100 M 2ME2 in the presence and absence of 10 M MG-132 for 4 hr. Equal amounts of protein from each cell lysate were
resolved by SDS-PAGE, transferred, and immunoblotted with antibodies against HIF-1 and TOPO-I. Arrows point to ubiquinated HIF-1 protein species.
ubiquitinylation and proteasomal degradation (Isaacs et al., Therefore, we sought to investigate whether there is any
correlation between the effects of 2ME2 on microtubules and2002; Mabjeesh et al., 2002) suggest that 2ME2 reduces HIF-1
protein levels through a translational-dependent pathway rather its effects on HIF-1. We assessed this by laser scanning confocal
microscopy (LSCM) in PC-3 cells treated with 2ME2 (Figure 3A).than affecting HIF-1 protein stability.
The cells were double-labeled with antibodies against -tubulin
(red) and HIF-1 (green) (Figure 3A). We observed a dose-2ME2 depolymerizes microtubules and inhibits nuclear
accumulation of HIF-1 dependent depolymerization of microtubules in the 2ME2-
treated cells (solid arrows) compared to the fine and intricate2ME2 has been shown to bind to the colchicine binding site of
tubulin (D’Amato et al., 1994) and to depolymerize microtubules microtubule network observed in untreated control cells. No
significant changes in the microtubule network were observedin endothelial (Fotsis et al., 1994) as well as in tumor cells (Aizu-
Yokota et al., 1995), resulting in mitotic arrest and cell death. in untreated cells after hypoxia. On the other hand, while HIF-1
was barely detectable under normoxic conditions, it predomi-However, there are also reports demonstrating that the antipro-
liferative activity of 2ME2 may occur independently of the desta- nantly accumulated in the nucleus after exposure to hypoxia
(Figure 3A, green staining). Nuclear localization of HIF-1 wasbilization of microtubules (Attalla et al., 1996) or by actually
stabilizing microtubules (Purohit et al., 1999). confirmed by double-labeling with DAPI (data not shown). 2ME2
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Figure 3. 2ME2 depolymerizes microtubules and impairs nuclear accumulation of HIF-1
A: PC-3 cells were treated overnight with the indicated concentrations of 2ME2 and then subjected to hypoxia, or they remained in normoxia for an
additional 6 hr. Cells were fixed and processed for double immunofluorescence labeling with anti-HIF-1 (green) and anti--tubulin (red) antibodies. Staining
was analyzed by confocal laser scanning microscopy. As a control, cells were also labeled with antibodies against -tubulin and HIF-1 (bottom panel).
2ME2 concentration are in M. Solid arrows point to cells with depolymerized microtubules. Dotted arrows depict nuclear boundaries. Scale bar, 10 m.
B: A similar experiment was performed with PC-3 cells treated with either taxol (TX) or vincristine (VCR) at the indicated concentrations in nM. Arrows depict
cells with depolymerized MTs, dashed arrows depict cells with hyperstabilized MTs forming bundles. Scale bar, 10 m.
C: PC-3 cells transiently transfected with pBI-GL V6L were treated with vehicle, 2ME2, taxol, or vincristine under normoxic or hypoxic conditions. The cells
were then harvested and analyzed for luciferase activity. The upper panel shows a Western blot developed with a HIF-1 antibody of NE of cells treated
with indicated drug concentrations under hypoxia.
D: PC-3 cells were treated overnight with either vehicle (0.01% DMSO) or indicated concentrations of Monastrol and processed for Western blotting and
confocal microscopy. Upper panel: equal amounts of protein from each samples were resolved by SDS-PAGE, and Western blotting was performed with
antibodies against HIF-1 or TOPO-I. Lower panel: PC-3 cells were fixed and processed for immunofluorescence labeling with anti--tubulin (red) antibody.
Staining was analyzed by confocal laser scanning microscopy. Solid arrows depict mitotic cells and dotted arrows interphase cells. Notice the difference
between a cell normally undergoing mitosis in control cells versus the abnormal monoastral mitotic spindles induced by Monastrol. Also notice that there
is difference between interhase microtubules between untreated and treated cells.
treatment significantly reduced the hypoxia-induced nuclear ac- to 2ME2, both taxol and vincristine blocked the hypoxia-induced
nuclear accumulation of HIF-1 (Figure 3B) while they had nocumulation of HIF-1. To examine whether these effects were
specific for the regulated subunit of HIF-1, HIF-1, we also effect on HIF-1 (Figure 3B and vincristine data not shown). To
confirm the data obtained by immunofluorescence and LSCM,tested the effects of 2ME2 on HIF-1. As seen at the bottom
panel of Figure 3A, 2ME2 treatment had no effect on either we analyzed HIF-1 protein levels and HIF-1 transcriptional
activity in cells treated with taxol and vincristine, utilizing 2ME2HIF-1 (green) levels or on HIF-1 subcellular localization. In
untreated cells, HIF-1 was localized predominantly in the nu- as a positive control. Consistent with what was observed with
2ME2 and with their effects on microtubules (Figure 3B), taxolcleus, and it was not further accumulated after hypoxia (data
not shown). and vincristine also reduced HIF-1 protein levels in a dose-
dependent manner (Figure 3C) and inhibited HIF-1 transcrip-To determine if the inhibition of HIF-1 was a general prop-
erty of MT-targeting agents or whether it was specific to 2ME2, tional activity (Figure 3C).
Since MT-targeting drugs are known to cause mitotic arrest,we tested other MT-disrupting agents that either destabilize
(vincristine) or stabilize (taxol) MTs (Figure 3B). Treatment of we wanted to exclude the possibility that the effects of 2ME2,
taxol, and vincristine on HIF-1 were nonspecific and reflectedPC-3 cells with taxol stabilized MTs, resulting in distinct microtu-
bules bundles (dashed arrows), while vincristine completely de- rather a “side effect” of mitotic arrest. Thus, we treated MDA-
MB231 cells with monastrol, a compound known to inducepolymerized microtubules (solid arrows) (Figure 3B). Similarly
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mitotic arrest by inhibiting the mitotic kinesin Eg5 but to have
no effect on the organization or function of the microtubule
cytoskeleton (Mayer et al., 1999). As clearly shown in Figure
3D, monastrol has no effect on HIF-1 protein levels (upper
panel) even at concentrations that induce a profound mitotic
arrest (lower panel). Consistent with previously published re-
ports on monastrol (Gagescu, 2000) and unlike MT-targeting
drugs, we also see no effect on interphase microtubules even
at concentrations at which monoastral spindles are observed
(Figure 3D, lower panel). Collectively, these results suggest that
the strong link between disruption of the microtubule cytoskele-
ton and inhibition of HIF-1 function is independent of mitotic
arrest.
Disruption of the MT cytoskeleton is required for
HIF-1 inhibition
The data with these three different classes of MT-targeting drugs
indicate that there is good correlation between the disruption
of the MT cytoskeleton and the inhibition of HIF-1. However,
the question remains of whether the effects of the MT-targeting
drugs on HIF-1 are independent from their effects on the MT
cytoskeleton. We addressed this question through a genetic
approach employing the 1A9 human ovarian carcinoma cells
and its taxol-resistant clone, 1A9/PTX10 (Giannakakou et al.,
1997). The 1A9/PTX10 cells are 30-fold resistant to taxol due
to an acquired -tubulin mutation at the taxol binding site, while
they retain sensitivity to all MT-depolymerizing agents (Gianna-
kakou et al., 1997) including 2ME2 (data not shown). To assess
whether drug-induced effects on microtubules are necessary
for inhibition of HIF-1, we treated the parental 1A9 and the
taxol-resistant 1A9/PTX10 cells with taxol and 2ME2 and pro-
cessed them for LSCM and Western blot analysis (Figure 4). As
expected, taxol had no effect on the microtubule network in
Figure 4. Drug-tubulin interaction is required for inhibition of HIF-1 protein
1A9/PTX10 cells even at 100 nM, whereas as little as 10 nM of expression
taxol was sufficient to bundle microtubules in the 1A9 parental 1A9 and PTX10 cells were plated in duplicate, subjected to the indicated
cells (Figure 4A). In addition, taxol inhibited HIF-1 protein levels treatments overnight followed by hypoxia for an additional 6 hr, and pro-
cessed for confocal microscopy (A) and Western blotting (B).in the parental 1A9 cells only, while it had almost no effect on
A: Cells were prepared for immunofluorescence staining with an anti-HIF-1 levels in 1A9/PTX10 cells. In contrast, 2ME2 depolymer-
-tubulin antibody followed by a secondary Alexa 568 antibody. Scale bar,ized MTs and reduced HIF-1 protein levels in both 1A9 and
10 m.
1A9/PTX10 cells (Figures 4A and 4B). Statistical analysis of three B: Equal amounts of protein from each cell lysate (NE) were resolved by
independent experiments (Figure 4C) shows that the ability of SDS-PAGE, transferred, and immunoblotted with antibodies against HIF-1
and TOPO-I.taxol and 2ME2 to inhibit HIF-1 levels correlates very well with
C: Densitometric quantification and statistical analysis of three independenttheir ability to affect cellular microtubules. These data extend
repetitions of the experiment described above. HIF-1/TOPO-I levels from
our previous observations and further suggest that disruption untreated cells of each experiment were given the value of 1 (100%). Rela-
of the normal function of the MT cytoskeleton is required for tive densitometry represents arbitrary units of the mean of the three repeti-
tions included in this analysis. Columns, means; bars, SD; n  3; * p  0.05;HIF-1 inhibition by MT-targeting drugs.
** p  0.01.
2ME2 inhibits angiogenesis at concentrations that
disrupt microtubules in vivo
The concentrations of 2ME2 required to observe the effects on
treatment, and at 150 mg/kg, there is a significant reduction inmicrotubules in vitro are much higher than those achievable in
tumor volume when compared to the vehicle-treated controlvivo. We employed a mouse orthotopic breast tumor model to
animals (Figure 5A). In addition, time-dependent tumor growthdetermine whether 2ME2 disrupts microtubules at the same
inhibition was also observed in two different animal models ofdoses at which it exhibits antitumor activity in vivo, and to see
human breast cancer cells (see Supplemental Figure S3 onif this also results in a decrease in the tumor microvascular
Cancer Cell website). To study the effects of 2ME2 on tumordensity. Animals were treated with 2ME2 or cyclophosphamide
vascularization, we performed immunohistochemical stainingas a non-MT-targeting chemotherapy drug. At the end of treat-
for CD31 in untreated and 2ME2-treated animals, and represen-ment, tumors were excised and processed to assess several
tative images are shown in Figure 5B. A clear reduction of CD31different parameters such as tumor volume, vascularization, and
staining is seen in the treated animals compared to controlsintegrity of the MT cytoskeleton. As seen in Figure 5A, a dose-
dependent reduction of tumor volume was observed with 2ME2 (Figure 5B, upper panel). Statistical analysis of microvessel den-
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Figure 6. 2ME2 inhibits angiogenesis at concentrations that depolymerize
microtubules in vivo
Animals treated with the indicated drugs as described above were sacri-
ficed after 33 days of treatment, and their tumors were processed for tubulin
immunofluorescence staining followed by confocal microscopy (A) and
tubulin Western blotting (B).
A: Tubulin immunofluorescence staining with an anti--tubulin antibody (red
staining) was performed in 50 m thick tumor sections from treated and
untreated animals as indicated. Representative treated animals from eachFigure 5. 2ME2 inhibits angiogenesis in a breast cancer orthotopic model
treatment cohort are shown as follows: animal #17, vehicle-treated animal;
A breast cancer orthotopic model was established using human MDA-MB- #19 and #21, 2ME2-treated animals at 150 mg/kg; #29, 2ME2-treated ani-
231 cells (2 	 106 ) implanted into the mammary fat pad of female BALB/ mal at 30 mg/kg; #11, cyclophosphamide-treated animal. Solid arrows de-
c nu/nu mice. Animals were treated with the indicated drugs as described pict the fine and intricate microtubule network from untreated animal #17
in Experimental Procedures, sacrificed after 33 days of treatment, and their or from cyclophosphamide-treated animal #11 (inset shows higher magni-
tumors were processed for tumor volume measurements (A) and CD31 fication of one cell from the entire field). Dashed arrows depict cells with
immunohistochemical staining (B). depolymerized microtubules from 2ME2- treated (150 mg/kg) animals #19
A: Tumor volume measurements were calculated using the formula width2 	 and #21. Inset in #19 shows a higher magnification of a cell with profound
length 	 0.52. Mean 
 SE of representative experiments is shown. * p  MT depolymerization. Dotted arrow in #21a depicts cells with abnormal
0.05 compared to 1% HPMC vehicle control; ** p  0.01 compared to PBS mitotic asters as a result of 2ME2 treatment. Dotted arrows in #21b (lower
control. magnification) depict cells with aberrant mitotic spindles abnormally ar-
B: MVD was determined by CD31 immunostaining in 10 paraffin-embedded rested in mitosis after 2ME2 treatment. Inset in #21b shows a higher magnifi-
tumor sections from each animal per cohort. Upper panel: a 20	 magnifi- cation of cells with aberrant mitotic spindles. Thick arrowheads point at
cation is shown; 2ME2, 150mg/kg. Lower panel: statistical analysis of MVD aberrant mitotic cells lining the vessel. Dashed arrow in #29 depicts cells
from all control and 2ME2-treated (150 mg/kg) animals. Columns represent with depolymerized MTs and dotted arrow cells with aberrant mitosis after
mean MVD and bars represent 
 SEM. treatment with 30 mg/kg 2ME2. Scale bars, 10 m.
B: The relative levels of polymerized and soluble tubulin from the tumors of
each treated animal were analyzed by Western blotting as described in
Experimental Procedures. Lanes P contain the polymerized form of tubulin
and lanes S contain the depolymerized soluble form of tubulin. The percent-sity (MVD) from CD31 immunostained tumors was performed
age of polymerized (% P) tubulin from the tumor of each animal was deter-by analyzing at least ten sections from each mouse per cohort. mined by dividing the densitometric value of polymerized tubulin by the
This analysis revealed a significant decrease (p  0.0001) in total tubulin content.
MVD in animals treated with 2ME2 compared to controls (Figure
5B, lower panel).
Then we sought to investigate whether the in vivo effects
of 2ME2 on MVD correlated with its antitubulin effects, as we kg 2ME2 (animal #19 and #21a, b) possess either completely
have seen in our experiments with cultured cells. The in vivo depolymerized MTs (dashed arrows) or multiple mitotic asters
effect of 2ME2 on MTs was evaluated by two different assays. (dotted arrows), which indicate aberrant mitotic arrest. The latter
First, we developed a highly sensitive method to allow qualitative is more evident in the lower magnification field shown for animal
assessment of the MT cytoskeleton integrity in vivo, using LSCM #21 (21b), where almost every cell displayed has aberrant mitotic
of tumor sections stained with an antibody against tubulin as spindles. The tumor cells from animals treated with 30 mg/
described in Experimental Procedures. As shown in Figure 6A, kg 2ME2 (animal #29) also have depolymerized MTs (dashed
the tumor cells from vehicle or cyclophosphamide-treated mice arrows) and multiple aberrant mitotic asters (dotted arrows).
This paper reports a qualitative assessment of microtubules in(animals #17 and #11, respectively) possess a fine, intricate,
and well-organized microtubule network (solid arrows). In con- vivo. A section of each tumor excised was processed for West-
ern blot for tubulin analysis in order to assess quantitatively thetrast, the tumor cells from the animals treated with 150 mg/
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Figure 7. 2ME2 inhibits HIF-2 and depolymerizes microtubules in endothelial cells
A: HUVEC cells were treated with 2ME2 and processed for HIF-2 Western blotting (upper panel) and confocal microscopy for tubulin staining (lower panel).
Scale bar, 10 m.
B: Double labeling immunofluorescence staining with antibodies against -tubulin (red) and anti-CD31 (green) was performed in tumor sections from
treated and untreated animals, as described above. Arrows depict MTs in endothelial cells. Insets show higher magnification of endothelial cell tubulin in
gray scale to enhance resolution. Notice the well-organized MT network of endothelial cells in the untreated tumor versus the depolymerized MTs observed
in endothelial cells in the 2ME2-treated tumors.
relative levels of polymerized and soluble tubulin following 2ME2 2ME2-treated animals were double-labeled with antibodies
against -tubulin (red staining) and CD31 (green staining). Care-treatment (Figure 6B). In this experiment, we adapted this tech-
nique previously developed to assess the effects of MT-tar- ful examination of the integrity of MTs in CD31-positive endothe-
lial cells revealed MT disruption in the treated animals comparedgeting drugs on cultured cells (Giannakakou et al., 1997). From
each tumor, the lanes labeled “P” contain the polymerized form to the undisturbed MT network in control animals (Figure 7B,
insets).of tubulin (MTs) and those labeled “S” the soluble form (/
tubulin dimers). Treatment with 2ME2 depolymerized MTs in a
dose-dependent manner. This is evidenced by the decrease Discussion
from 70% of polymerized tubulin in the vehicle-treated animal
to 3%–9% observed in the animals treated with 2ME2. Thus, Angiogenesis is one of the important biological processes re-
we have demonstrated by two independent assays that 2ME2 quired to support tumor growth beyond a certain threshold
depolymerizes MTs in vivo (Figure 6) at concentrations that size. Therefore, the development of angiogenesis inhibitors has
inhibit growth and vascularization of tumors (Figure 5). recently become an attractive new strategy to combat cancer.
Careful examination of the in vivo MT staining after 2ME2 In this study, we have identified a novel molecular mechanism
treatment suggested that 2ME2 may also have an effect on by which 2ME2, an antitumor agent and angiogenesis inhibitor
endothelial cell tubulin, as depicted by the aberrant mitoses currently in phase I/II trials, exerts its activity. Our results show
seen in cells that line the vessel in animal #21b (Figure 6A, thick that 2ME2 depolymerizes MTs and downregulates HIF-1 pro-
arrowheads). This observation prompted us to investigate the tein levels and HIF transcriptional activity in an oxygen- and
effects of 2ME2 on endothelial cells in vitro and in vivo. As proteasome-independent manner (Figures 1 and 2). Most impor-
shown in Figure 7A and similarly to cancer cells (Figures 1–4), tantly, we demonstrate that at concentrations that inhibit tumor
growth and vascularization in vivo, 2ME2 effectively depolymer-2ME2 treatment resulted in a dose-dependent inhibition of HIF-
2 protein in human umbilical vein endothelial cells (HUVEC) izes tumor MTs.
In vitro, 2ME2 has been shown to compete with colchicine(upper panel), which correlated with extensive microtubule de-
polymerization (lower panel). Decreased DNA binding activity of for tubulin binding and to disrupt interphase MTs leading to
mitotic arrest and cell death in cultured cancer cells (CushmanHIF measured by EMSA was observed in 2ME2-treated HUVEC
cells compared to control untreated cells (data not shown). et al., 1997; D’Amato et al., 1994; Seegers et al., 1997). In
addition, when we treated HUVEC with 2ME2, we observed aWe next examined the effects of 2ME2 on endothelial cell
tubulin in vivo (Figure 7B). Tumor sections from untreated or dose-dependent MT depolymerization at concentrations similar
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to those used in tumor cells (Figure 7A). The antiangiogenic HIF (Figure 4). However we have not yet determined what the
properties of this compound, however, had not been correlated signaling events are that link MT disruption to HIF-1 inhibition.
previously with its effects on MTs. Other MT-targeting com- Interestingly, a recent study has shown that VHL is a tubulin-
pounds have also been shown to possess varying degrees of associated protein that helps stabilize interphase microtubules,
antiangiogenic activity, including the colchicine site agents potentially identifying a new role for pVHL function in VHL dis-
combretastatins (Dark et al., 1997; Grosios et al., 1999; Tozer ease (Hergovich et al., 2003). However, how the pVHL stabilizing
et al., 2001) and ZD6126 (Blakey et al., 2002) and the taxane effects on MTs may be linked to the VHL-HIF functional regula-
site agents, such as taxol, (Belotti et al., 1996; Klauber et al., tion is currently unclear (Ratcliffe, 2003). Future studies are
1997) docetaxel (Sweeney et al., 2001), and IDN 5390 (Tarabo- warranted to increase our understanding of the molecular mech-
letti et al., 2002). The above studies led to the hypothesis that anisms that regulate these pathways.
the antivascular effects of MT-targeting agents derive from their Taken together, our results show that disruption of in-
ability to selectively inhibit the growth of endothelial cells in terphase MTs results in repression of HIF-1, likely at the level
tumor vessels, producing vascular shutdown and massive tumor of translation, which in turn leads to inhibition of HIF-1 transcrip-
necrosis. Our data show that 2ME2 affects in vivo tubulin in tional activity, including downregulation of VEGF expression.
both the tumor and endothelial cell compartments (Figures 6 and We have further determined that inhibition of HIF-1 by 2ME2
7), which suggests that 2ME2 may interfere with the crosstalk or other MT-targeting compounds occurs downstream of drug-
between cancer and endothelial cells further contributing to the tubulin interaction. This finding provides mechanistic insight into
antitumor and antiangiogenic activity of 2ME2. the antiangiogenic mechanism of action reported for several
Decreased VEGF protein levels after 2ME2 treatment have MT-targeting compounds and supports the hypothesis that tu-
been reported previously (Banerjeei et al., 2000; Chauhan et al., bulin-targeting drugs inhibit both tumor cell growth and tumor
2002); however, the molecular mechanism responsible for this vascularization following disruption of the MT cytoskeleton. The
decrease had not been identified. Our data show that 2ME2 further characterization of the molecular signals linking the dis-
interferes with the downstream activation of HIF-1 target genes, ruption of the MT cytoskeleton with the downregulation of HIF-
only one of which is VEGF, in response to hypoxia (Figure 2). mediated angiogenesis are likely to identify novel targets for
Thus, our current hypothesis is that the antitumor/antiangio- the development of new anticancer therapies.
genic activity of 2ME2 likely results from both the inhibition of We believe that pharmacologic inhibition of HIF-1 and par-
the normal function of tumor MTs and the inhibition of the HIF- ticularly HIF-regulated genes that are important for cancer cell
transcriptome. This hypothesis is supported by data in the litera- survival may be more advantageous than HIF-gene inactivation
ture showing that inhibition of VEGF in vivo by the recombinant therapeutic approaches. Conflicting results have emerged from
humanized antibody directed against VEGF (rhuMAb-VEGF) led HIF knockout models that showed both accelerated and re-
to only a 25% inhibition of angiogenesis, whereas 2ME2 inhib- tarded tumor growth (Carmeliet et al., 1998; Hopfl et al., 2002;
ited angiogenesis by 63% (Sweeney et al., 2001). This result is Maxwell et al., 1997; Ryan et al., 1998; Ryan et al., 2000), sug-
in agreement with our in vivo data where a 64% inhibition of gesting that genetic inactivation of HIF may not be sufficient to
angiogenesis was obtained after treatment with 150 mg/kg inhibit tumor growth and angiogenesis due to compensatory
2ME2 (Figure 6), and it further suggests that the 2ME2 antiangio- survival mechanisms acquired by the cancer cells.
genic activity might not be solely attributed to inhibition of VEGF. 2ME2 is currently in phase I/II clinical trials in breast, meta-
Although we attempted to show that 2ME2 inhibited HIF-1 in static breast, and prostate cancer. The preliminary results from
vivo, we were unable to do so because of the technical challenge these trials show promising responses without any serious drug-
in staining HIF-1 in sections form xenograft tumors, unlike our related adverse effects even when 2ME2 is administered at
earlier success in staining patients’ specimens for HIF-1 from doses of 1,000–1,200 mg/day (Lakhani et al., 2003). Herein, we
a wide variety of different cancers (Zhong et al., 1999). While show that 2ME2 is a lead compound that has a dual effect on
we have not been able to confirm all of our in vitro observations MTs, a validated anticancer drug target, and HIF, which we
in vivo, our data support the hypothesis that 2ME2 affects MTs believe is an important survival factor in cancer.
and its downstream effects on HIF pathway lead to inhibition
of tumor vascularization in vivo. We believe further studies using Experimental procedures
human cancer cells lacking HIF-1 and HIF-2 activity are war-
Chemicals and antibodiesranted to conclusively elucidate the important steps involved in
2ME2 was purchased from Tetrionics (Madison, Wisconsin) and 0.1 mMthis process in vivo.
stock solutions were made in DMSO and stored in aliquots at 80C. TheIn our experiments, we have demonstrated that taxol and
compound was diluted in incubation media immediately prior to each experi-vincristine also inhibited HIF-1 levels and HIF-1 transcriptional
ment. Thawed stock solutions were used once and discarded. Vincristine
activity (Figure 3). Despite the “opposite” effects of taxol and was from Eli-Lilly (Indianapolis, Indiana), Paclitaxel and Cyclophosphamide
vincristine on MT structure (stabilization versus destabilization), were from Sigma (St. Louis, Missouri). MG-132 (Z-Leu–Leu–Leu-aldehyde)
it is not surprising that both drugs had similar effects on HIF was purchased from Alexis Biochemicals (San Diego, California). Monastrol
since they both disrupt the organization and equally affect the was from AG Scientific, Inc. (San Diego, California). The following primary
antibodies were used: rat anti--tubulin (Chemicon International, Temecula,normal function of the MT cytoskeleton. We further showed
California), mouse anti-HIF-1 (BD Biosciences, San Diego, California), ratthat HIF inhibition is not a consequence of mitotic arrest since
anti-CD31 (PharMingen, San Diego, California), polyclonal antibody againstmonastrol, a non-MT-targeting drug that induces mitotic arrest
human HIF-2 and monoclonal HIF-1 (Novus Biologicals, Littleton, Colo-
(Mayer et al., 1999), was not able to downregulate HIF-1 levels rado), human actin antibody from Santa Cruz Biotechnology, Inc. (Santa
(Figure 3D). We have also demonstrated that the alterations in Cruz, California), and polyclonal human antibody to human topoisomerase
the MT cytoskeleton resulting from the interaction of the MT- I (TOPO-I) (TopoGEN, Columbus, Ohio). Rabbit polyclonal antibodies to c-Jun,
c-Fos, NF-B p50, and NF-B p65 were from Geneka Biotechnology, Inctargeting drugs with tubulin are required for the inhibition of
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(Montre´al, Que´bec, Canada). Secondary antibodies were horseradish peroxi- various times. Subsequently, the cells were washed twice with ice-cold PBS,
lysed, and subjected for immunoprecipitation using anti-HIF-1 antibody asdase-conjugated (Amersham Pharmacia Biotech, Piscataway, New Jersey),
Alexa Fluor 488 goat anti-mouse (Molecular Probes, Eugene, Oregon), Alexa previously described (Mabjeesh et al., 2002).
Fluor 568 goat anti-rat (Molecular Probes, Eugene, Oregon), Rhodamine
Red-X mouse anti-rat (Jackson ImmunoResearch, West Grove, Baltimore). Tumor models and immunohistochemistry
Female 8- to 10-week-old BALB/c nu/nu mice (Jackson Laboratories, Bar
Harbor, Maine) were injected in the mammary fat pad with 2 	 106 MDA-Cell lines
Human breast cancer MDA-MB-231 cells were maintained in DMEM and MB-231 cells. Daily oral administration of 2ME2 was initiated when the
tumors became palpable (4–5 mm diameter) on day 20 after implantation.human prostate cancer PC-3 cells; 1A9 human ovarian carcinoma cells
and its paclitaxel-resistant subline 1A9/PTX10 were cultured in RPMI 1640; A suspension of 2ME2 was prepared by homogenization in an aqueous
solution of 0.5% methylcellulose (Sigma) using a Kinematica polytron (Brink-HUVEC were cultured in M199 media. All media were supplemented with
10% FBS and antibiotics. Cells were cultured at 37C in a humidified atmo- mann, Westbury, New York). At the end of the dosing regimen on day 53
(treatment duration was 33 days), animals were sacrificed and tumor volumessphere and 5% CO2 in air. For hypoxic exposure, cells were placed in a
sealed modular incubator chamber (Billups-Rothenberg, Del Mar, California) were calculated as width2 	 length 	 0.52. Upon termination of the dosing
regimen, animals were euthanized with 20 mg/100 g BW of phenobarbitalflushed with 1% O2, 5% CO2, and 94% N2.
(Sigma), and tumors were excised as quickly as possible and cut into 1
mm2 pieces. One piece of tumor was dounced and placed into 200 l of2ME2 treatment of cells
microtubule-stabilizing buffer and processed for the tubulin polymerizationCells were seeded in culture dishes and grown until 70% confluence. The
assay (for details, see below). The rest of tumor pieces were fixed with 3.7%medium was then replaced with a new medium containing either vehicle
(0.1% DMSO) or 2ME2 at the concentrations indicated in the figures for formaldehyde, 0.05% glutaraldehyde, and 0.5% Triton X-100 in PHEMO
overnight at 37C. The following day, cells were exposed to hypoxia or left buffer for 30 min at room temperature. Then they were transferred into 4%
under normoxia for 6 hr. The cells were then washed twice with ice-cold formaldehyde in 0.1 M sodium cacodylate buffer (Sigma) (pH 7.3) for an
PBS, harvested, and nuclear extract (NE) was prepared as described (Jiang additional 4 hr. Tumor pieces were stored at 4C in the same buffer until
et al., 1996), or alternately, a whole-cell extract (WCE) was prepared by they were immunostained for -tubulin, as described above, and CD-31.
lysing the cells with 100 mM potassium phosphate (pH 7.8) and 0.2% Triton
X-100 supplemented with protease and phosphatase inhibitors. Immunohistochemical determination of CD 31/PECAM-1
For immunohistochemistry, tumors were fixed in 10% buffered formalin
Immunoblot analysis (Sigma). Paraffin-embedded tissue was sectioned at 5 m and mounted on
Proteins (30–60 g/lane) from WCEs or NEs were resolved by 7.5% SDS- Superfrost slides (Fisher Scientific, Co., Houston, Texas). Sections were
PAGE, electrotransferred to nitrocellulose membrane, and incubated with deparaffinized in xylene, subsequently immersed in graded alcohol (100%,
the indicated primary antibodies, followed by horseradish peroxidase-conju- 95% ethanol), rehydrated in ddH2O and Tris buffer. Sections were then
gated secondary antiserum. Immunoreactivity was visualized by enhanced treated with Protinase K (Roche Indianapolis, Indiana), washed in Tris-buffer,
chemiluminescence reagent (Amersham Biosciences, Piscataway, New Jer- blocked for endogenous peroxidase activity by use of 3% hydrogen peroxide
sey). For sequential blotting with additional antibodies, the membranes were in methanol for 20 min. After blocking sections with TNB block for 45 min
stripped using a restore Western blot stripping buffer (Pierce, Rockford, (NEN Life Science Products, Inc. Boston Massachusetts), sections were
Illinois) and reprobed with the indicated antibodies. incubated with anti-CD31 rat anti-mouse antibody (1:250 dilution) at 4C
overnight (PharMingen, San Diego, California). Slides were then washed TNT
ELISA for VEGF wash buffer (NEN), incubated with species-specific biotinylated secondary
VEGF concentration in media from treated cells was determined using ELISA antibody for 30 min (1:200 dilution, Vector Laboratories, Burlingame, Califor-
kit for VEGF protein (R & D Systems, Inc., Minneapolis, Minnesota) according nia). After secondary incubation slides were washed in TNT buffer, sections
to the manufacturers’ instructions. The results were expressed as concentra- were amplified with tyramide-horderdase peroxidase (NEN) and visualized
tion of VEGF (pg/ml) per the total protein amount from each well. by incubating the slides with 3, 3-diaminobenzidine (Vector). The slides
were counterstained with Gills Hemotoxylin III (Sigma), rinsed, and immersed
Transient transfections and reporter gene assay briefly in 1% ammonia solution for nuclei binding. Finally, slides were hy-
PC-3 cells were transfected with 1g/well of a reporter plasmid (pBI-GL V6L) drated and mounted with cytoseal (VWR International, West Chester, Penn-
containing HREs from the VEGF gene as previously described (Mabjeesh et sylvania) and covered with Fisherfinest glass cover slips (Fisher). For negative
al., 2002; Post and Van Meir, 2001). controls, the exact procedure was done with either the omission of the
primary antibody or the secondary.
Isolation and analysis of RNA
Total RNA was isolated using TRIzol Reagent (Life Technologies, Inc), and Quantification of MVD
Northen blotting was performed with probes specific for human HIF-1, For quantification of CD31, tumor sections that stained positive for CD31
VEGF 165, endothelin 1 (ET-1), Glut-1 glucose transporter, and -actin (Am- vessels were used in the analysis. Microvasular density (MVD) was measured
bion, Inc., Austin, Texas) as described (Wang et al., 1995). by using Bioquant Image Analysis System (PAI, Frederick, Maryland). To
quantify the vessels, ten areas at 168 m2 per field at 	200 were captured
for each tumor using Olympus BX 40 microscope.HIF-1 protein translation assay
PC-3 cells were plated into 6-well plates and grown to 70% confluence.
Cells were pretreated overnight with 25 M 2ME2 or DMSO (0.025% vol/ Immunofluorescence and confocal microscopy
vol). Then medium was changed to methionine- and cysteine-free as well A. Cell lines
as serum-free RPMI 1640 medium for 2 hr. After 2 hr, cells were labeled Exponentially growing cells were plated on 12 mm glass coverslips (Fisher
by incubation with methionine- and cysteine-free medium containing 35S- Scientific, Pittsburgh, Pennsylvania) into 24-well plates and cells were al-
methionine (ICN Biomedicals, Inc., California) at a final concentration of 100 lowed to attach overnight. The following day, cells were treated with the
Ci/well at 37C for the indicated time in the figure. Subsequently, the cells indicated drugs for 16 hr and subjected to hypoxia for an additional 6 hr.
were washed twice with ice-cold PBS, lysed, and subjected for immunopre- Cells were fixed with PHEMO buffer (PIPES 0.068M, HEPES 0.025 M, EGTA
cipitation using anti-HIF-1 antibody and protein G-agarose beads (Pierce, 0.015 M, MgCl2 0.003 M, 10% DMSO, pH 6.8) containing 3.7% formalde-
Illinois) as previously described (Mabjeesh et al., 2002). hyde, 0.05% glutaraldehyde, 0.5% Triton X-100 for 10 min at room tempera-
ture. Coverslips were blocked in 10% goat serum/PBS for 10 min and
processed for double-labeling immunofluorescence with rat anti--tubulin,Pulse chase assay
PC-3 cells grown in 6-well plates were labeled with 35S-methionine as de- mouse anti HIF-1, and mouse anti-HIF-1 antibodies. The secondary anti-
bodies were Alexa Fluor 488 goat anti-mouse antibody and Alexa Fluor 568scribed above. The radioactive medium was then removed and cells were
recultured in complete medium with 0.1% DMSO or 100 M 2ME2 for goat anti-rat antibody antibodies. Coverslips were then mounted onto glass
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R., and Taraboletti, G. (1996). The microtubule-affecting drug paclitaxel hasslides and examined with a Zeiss axioplasm laser scanning confocal micro-
antiangiogenic activity. Clin. Cancer Res. 2, 1843–1849.scope using a Zeiss 	100 1.3 oil-immersion objective.
B. Tumor sections Birner, P., Schindl, M., Obermair, A., Plank, C., Breitenecker, G., and Ober-
Animals were treated as described above. For tubulin immunofluorescence huber, G. (2000). Overexpression of hypoxia-inducible factor 1alpha is a
followed by LSCM, 1 mm2 pieces of tumor from each animal were fixed in marker for an unfavorable prognosis in early-stage invasive cervical cancer.
PHEMO buffer containing 3.7% formaldehyde, 0.05% glutaraldehyde, 0.5% Cancer Res. 60, 4693–4696.
Triton X-100 for 1–2 hr at room temperature. Following fixation, tumor pieces
Birner, P., Schindl, M., Obermair, A., Breitenecker, G., and Oberhuber, G.were stored in 4% paraformaldehyde in 0.1% sodium cacodylate at 4C for
(2001). Expression of hypoxia-inducible factor 1alpha in epithelial ovarianup to a month before further processing. Fixed tumor sections were embed-
tumors: its impact on prognosis and on response to chemotherapy. Clin.ded in low-melting agarose (Sigma) and 50 m sections were obtained by
Cancer Res. 7, 1661–1668.vibratome sectioning at low speed (Vibratome Series 1000 Sectioning Sys-
tem) as previously described (Hale and Matsumoto, 1993). Sections were Blakey, D.C., Westwood, F.R., Walker, M., Hughes, G.D., Davis, P.D., Ashton,
then processed for -tubulin immunofluorescence staining and laser scan- S.E., and Ryan, A.J. (2002). Antitumor activity of the novel vascular targeting
ning confocal microscopy as described above. agent ZD6126 in a panel of tumor models. Clin. Cancer Res. 8, 1974–1983.
Blancher, C., Moore, J.W., Talks, K.L., Houlbrook, S., and Harris, A.L. (2000).Tubulin polymerization assay
Relationship of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expres-
The percent of polymerized tubulin from the tumors of the treated animals
sion to vascular endothelial growth factor induction and hypoxia survival in
was assessed as previously described (Giannakakou et al., 1997). human breast cancer cell lines. Cancer Res. 60, 7106–7113.
Bos, R., Zhong, H., Hanrahan, C.F., Mommers, E.C., Semenza, G.L., Pinedo,Data analysis
H.M., Abeloff, M.D., Simons, J.W., van Diest, P.J., and van der Wall, E. (2001).Experiments presented in the figures are representative of three or more
Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. J.different repetitions. Quantification of band densities was performed using
Natl. Cancer Inst. 93, 309–314.the public domain NIH Image (version 1.61). Statistical analysis was per-
formed using a one-way ANOVA test (p  0.05 was considered statistically Brahimi-Horn, C., Berra, E., and Pouyssegur, J. (2001). Hypoxia: the tumor’s
significant). gateway to progression along the angiogenic pathway. Trends Cell Biol. 11,
S32–S36.
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